cedure is in suspended animation and there it should remain until further large-scale trials guide us as to the best way forward, particularly in relation to patient selection. If primary PTCA is to be adopted into routine practice then it should be in the context of a strategy covering all opportunities for intervening from the moment symptoms begin. Such a strategy might reduce the high mortality in many patients with acute myocardial infarction more than the introduction of a single, expensive procedure for those '7-9 Indeed, it is probably the best treatment for achieving rapid reperfusion in such high risk subsets. '9 group.bmj.com on June 26, 2017 -Published by http://heart.bmj.com/ Downloaded from Although the initial costs of primary PTCA are higher than thrombolytic therapy with streptokinase, use of anistreplase and r-tPA (alteplase), which are more expensive, will narrow the gap. Moreover, the in-hospital stay is shorter and readmission rates lower after PTCA than after thrombolytic therapy'3 20 and at one year the costs of primary PTCA were similar to streptokinase therapy and cheaper than treatment with r-tPA."3
Over and above these benefits, the necessary immediate coronary arteriography provides crucial information for treatment stratification. Those patients with left main coronary artery stenosis, severe three vessel coronary artery disease, or occluded vessels that are unsuitable for PTCA can be referred for coronary artery bypass surgery. Conversely, those with a patent or insignificant infarctrelated vessel may be selected for medical treatment rather than unnecessary thrombolytic therapy.
There are overwhelming advantages to primary PTCA in acute myocardial infarction but there are also drawbacks. Some of these are consequent to the nature of the procedure whereas others are major resource and manpower issues. In common with most other UK centres, most of our patients with acute myocardial infarction are treated with intravenous thrombolytic therapy. However, in recent years we have performed primary and rescue PTCA in over 100 patients. Patients underwent primary PTCA if they presented when a cardiologist was available and the cardiac catheter laboratory was unoccupied or about to become so. Thus most patients were treated in the evenings, early hours of the morning, and at the weekend. Initially we were motivated to continue this demanding activity because of our research interests and because we were impressed by the angiographic and clinical results achieved, but it soon became obvious that resources were not sufficient to offer a district service let alone a regional one. In the first 50 patients without cardiogenic shock that we treated by primary PTCA, the median time from onset of pain to presentation was 120 minutes (range 10-420 minutes) and the median time from presentation to recanalisation was 90 minutes (range 20-215 minutes). Recanalisation was usually achieved within minutes of the patient entering the catheter laboratory. Sixty two per cent of patients had multivessel disease and PTCA was performed to the right coronary artery in 40%, left anterior descending in 44%, left circumflex in 12%, intermediate artery in 2%, and saphenous vein graft in 2%. In 96% of patients only the infarct-related artery was attempted. The remaining 4% had other critical stenoses or occluded vessels dilated. Intracoronary thrombus was seen in 68% of patients and adjunctive intracoronary thrombolytic therapy was used in 63% of these to help to disperse persistent thrombus. The primary success rate with PTCA was high: TIMI 3 flow was achieved in all patients. In two patients non-occlusive dissection developed in the right coronary artery (in one this may have been induced by the guide catheter). Most vessels (92%) remained patent at 24 hours and in some left ventricular function showed a considerable visible improvement in those patients who had prompt reperfusion. Of the four reocclusions, three were promptly reopened by repeat PTCA and one in a distal right coronary artery was left alone. Complications included severe arrhythmias in 18 (36%) and severe hypotension requiring fluids and inotropes in 10 (20%); however, emergency coronary artery bypass grafting was not necessary and there were no deaths. Myocardial rupture and femoral artery complications did not occur although intravenous heparin was continued for up to 48 hours after PTCA. The high success rate and low major complication rate may be the result of our careful selection of what we thought to be "ideal relatively low-risk" cases, yet over 60% of these had multivessel disease at angiography.
If the mortality associated with myocardial infarction is confirmed to be significantly lower after PTCA than after conventional thrombolytic therapy (as a pooled analysis of the three major prospective clinical trials indicates" [24] [25] [26] 
